Premium
Can serum level of N‐terminal pro B‐type natriuretic peptide be used in patients with psoriasis as a predictor of cardiovascular disease?
Author(s) -
ShahidiDadras Mohammad,
Niknezhad Nasim,
Niknejad Nakisa,
Zargari Omid
Publication year - 2019
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.12865
Subject(s) - medicine , psoriasis , interquartile range , natriuretic peptide , psoriatic arthritis , body mass index , gastroenterology , lipid profile , metabolic syndrome , confidence interval , arthritis , endocrinology , cardiology , obesity , immunology , cholesterol , heart failure
Past studies have reported associations between psoriasis, metabolic syndrome, and atherosclerotic cardiovascular disease. According to studies, N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) is a useful screening test for cardiac disease. We examined the serum NT‐proBNP level in patients with psoriasis and compared them with nonpsoriatic healthy control subjects. Sixty‐one patients with psoriasis were enrolled, along with 61 age, sex, and body mass index (BMI) matched control subjects. In both groups, NT‐proBNP serum levels and lipid profile parameters were investigated. Means and 95% confidence intervals (CIs) were reported. The median serum concentration of NT‐proBNP was higher in psoriatic patients than the control group (26.67 [interquartile range (IQR): 15.15–43.03 and range: 5–250] vs. 17.45 [IQR: 12.35–20.80 and range: 5–45.09, p < 0.0001). NT‐proBNP serum level in psoriatic arthritis patients (11%; 55.6 ± 25.7 pg/mL, 95% CI: 31.9–79.4 pg/mL) was higher than psoriasis patients without arthritis (35.8 ± 40.6 pg/mL, CI: 24.7–46.9, p < 0.001). NT‐proBNP levels were also positively correlated with BMI, lipid profile, and disease duration. NT‐proBNP is elevated in patients with psoriasis, consistent with the high risk of cardiovascular disease associated with psoriasis.